Table 3.
Current registered clinical trials “Not yet Recruiting” COVID‐19 patients for stem cells‐based therapies
| Trial number/identification | Condition or disease | Cell type used as intervention | Phase |
|---|---|---|---|
| NCT04428801 | COVID‐19 | Autologous adipose‐derived stem cells | II |
| NCT04302519 | COVID‐19 | Dental pulp‐MSCs | Early phase I |
| NCT04429763 | COVID‐19 | UC‐MSCs | II |
| NCT04315987 | COVID‐19 pneumonia | MSCs | II |
| NCT04349540 | COVID‐19 | Allogeneic hematopoietic stem cells | NA |
| NCT04390152 | Acute respiratory distress syndrome | WJ‐MSCs | I, II |
| NCT04348461 | COVID, respiratory distress syndrome | Allogeneic and expanded adipose tissue‐derived MSCs | II |
| NCT04371601 | COVID‐19 pneumonia | UC‐MSCs | I |
| NCT04362189 | COVID‐19 pneumonia | Allogeneic AT‐MSCs | II |
| NCT04393415 | COVID‐19 | Cord blood (CB) stem cells | NA |
| NCT04397796 | COVID | Allogenic BM‐MSCs | I |
| NCT04377334 | COVID, ARDS | Allogeneic BM‐MSCs | II |
| NCT04400032 | COVID‐19, ARDS | BM‐MSCs | I |
| NCT04398303 | COVID‐19 pneumonia | Allogenic human umbilical‐derived MSCs and allogenic human umbilical‐derived MSCs conditioned medium | I, II |
| NCT04345601 | COVID‐19, ARDS | BM‐MSCs | Early phase I |
| NCT04299152 | SARS pneumonia | CB stem cells | II |
| NCT04346368 | COVID‐19 | BM‐MSCs | I, II |
| NCT04273646 | COVID‐19, novel coronavirus pneumonia | UC‐MSCs | NA |
| ChiCTR2000030224 | Coronavirus disease 19 | MSC | II |
| ChiCTR2000030173 | Coronavirus disease 19 | UC‐MSCs | 0 |
| ChiCTR2000030261 | Coronavirus disease 19 infection, viral pneumonia | MSCs‐derived exosomes | 0 |
| ChiCTR2000030116 | Coronavirus disease 19 infection, respiratory distress syndrome, viral pneumonia | UC‐MSCs | II |
| ChiCTR2000030138 | Coronavirus disease 19 infection, viral pneumonia | UC‐MSCs | II |
| ChiCTR2000030088 | Coronavirus disease 19 infection, viral pneumonia | WJ‐MSCs | 0 |
| ChiCTR2000029816, ChiCTR2000029817 | Coronavirus disease 19 infection, pneumonia | CB‐NK cells + CB‐MSCs | 0 |
| NCT04276987 | Coronavirus | MSCs‐derived exosomes | I |
Abbreviations: ARDS, severe acute respiratory distress syndrome; AT‐MSC, adipose tissue‐derived mesenchymal stem cell; BM‐MSC, bone‐marrow‐derived mesenchymal stem cell; COVID‐19, novel coronavirus disease; MSC, mesenchymal stem cell; NK, natural killer; NA, not applicable; SARS, severe acute respiratory syndrome; UC‐MSC, umbilical cord‐derived mesenchymal stem cell; WJ‐MSC, Wharton's jelly‐derived mesenchymal stem cell.